Med-life discoveries
Med-Life Discoveries is developing synthetic plasmalogen therapies to treat biogenesis disorders, including Rhizomelic Chondrodysplasia Punctata and various neurological conditions such as Alzheimer's and Parkinson's disease. Their approach targets plasmalogen deficiency, which is linked to these disorders, by providing clinical-grade treatments currently undergoing regulatory safety and efficacy studies.
- Biotechnology
- Digital Health
Funding
Raised to date
$13.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Certain genetic and neurodegenerative diseases, such as Rhizomelic Chondrodysplasia Punctata (RCDP), Alzheimer's, Parkinson's, and multiple sclerosis, are associated with a deficiency in plasmalogens, a class of ether lipids critical for cellular function. Current treatment options are limited, and there is a need for therapies that can directly address this plasmalogen deficiency.
Solution
Med-Life Discoveries (MLD) is developing clinical-grade synthetic plasmalogen therapies designed to treat diseases associated with plasmalogen deficiency. Their approach focuses on therapeutically augmenting plasmalogen levels to manage and potentially mitigate the progression of these conditions. MLD's plasmalogen drugs are undergoing formal regulatory safety and efficacy studies. The company also develops patented screening tests for colorectal cancer, pancreatic cancer, and Alzheimer's disease.
Target Audience
The primary target audience includes patients suffering from Rhizomelic Chondrodysplasia Punctata (RCDP) and individuals with neurological conditions associated with plasmalogen deficiency, as well as healthcare providers specializing in these areas.
Features
- Synthetic plasmalogen therapies designed to augment plasmalogen levels in patients.
- Focus on treating Rhizomelic Chondrodysplasia Punctata (RCDP) and neurological conditions like Alzheimer's, Parkinson's, and multiple sclerosis.
- Clinical-grade compounds undergoing regulatory safety and efficacy studies.
- Patented screening tests for early detection of colorectal cancer, pancreatic cancer, and Alzheimer's disease.